Effects of LAIR-1 on hepatocellular carcinoma cell proliferation and invasion via PI3K-AKT-mTOR pathway regulation.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
08 2023
Historique:
revised: 17 07 2023
received: 10 02 2023
accepted: 31 07 2023
medline: 1 9 2023
pubmed: 30 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) is one of the common malignant tumors. Although surgical resection is the best treatment for HCC, many patients with HCC are found to have metastases at the time of initial diagnosis and lose the opportunity for radical treatment. Therefore, the study of the invasion and metastasis of HCC has always been the focus of HCC research. This study aimed to assess the influence of LAIR-1 on HCC cell proliferation and invasion and the relevant mechanisms involved in this process. Immunocytochemical staining assay, quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting (WB) were used to detect the expression of LAIR-1mRNA and protein in healthy human hepatocyte LO2 and the HCC cell lines HepG2, Bel-7402, MHCC97-H, and Huh-7. Then, we evaluated the cell viability, colony formation, and invasion of MHCC97-H and Huh-7 cells in each group by silencing or overexpressing LAIR-1 expression in MHCC97-H and Huh-7 cells, respectively. WB was used to detect the expression levels of PI3K-AKT-mTOR pathway related proteins. Our findings showed that LAIR-1 can inhibit cell viability, colony formation and invasion in vitro. Meanwhile, LAIR-1 significantly downregulated the expression of PI3K, p-AKT and p-mTOR, which were abolished by the PI3K inhibitor, LY294002. Our study revealed that LAIR-1 inhibited cell proliferation and invasion, probably via suppressing the PI3K-AKT-mTOR pathway.

Identifiants

pubmed: 37647449
doi: 10.1002/iid3.982
pmc: PMC10465992
doi:

Substances chimiques

Phosphatidylinositol 3-Kinases EC 2.7.1.-
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e982

Informations de copyright

© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

Head Neck. 2019 Apr;41(4):1080-1086
pubmed: 30549148
Curr Res Transl Med. 2020 Aug;68(3):119-124
pubmed: 32690423
Eur Rev Med Pharmacol Sci. 2012 Oct;16(11):1599-604
pubmed: 23111978
Mol Immunol. 2017 Jul;87:132-140
pubmed: 28433890
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Biomed Pharmacother. 2018 May;101:115-122
pubmed: 29477471
Bioact Mater. 2021 Apr 07;6(11):3744-3755
pubmed: 33898875
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Immun Inflamm Dis. 2023 Aug;11(8):e982
pubmed: 37647449
Oncol Lett. 2015 Aug;10(2):681-686
pubmed: 26622553
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Biochem Biophys Res Commun. 2021 May 7;552:44-51
pubmed: 33743348
Exp Ther Med. 2016 Dec;12(6):3699-3705
pubmed: 28105100
Int J Gen Med. 2022 Jun 23;15:5763-5773
pubmed: 35770053
Aging (Albany NY). 2020 Sep 5;12(16):16142-16154
pubmed: 32628130
Cancer Med. 2020 Feb;9(3):1141-1151
pubmed: 31830378
Oncotarget. 2017 Oct 30;8(57):97428-97438
pubmed: 29228622
Oncol Rep. 2016 Jun;35(6):3614-22
pubmed: 27109804
J Hepatol. 2014 Apr;60(4):855-65
pubmed: 24308993
Biomedicines. 2021 Nov 08;9(11):
pubmed: 34829868
Expert Opin Investig Drugs. 2019 Feb;28(2):131-142
pubmed: 30574817
Contrast Media Mol Imaging. 2022 Jul 14;2022:2109908
pubmed: 35909586
Front Immunol. 2021 Oct 07;12:733561
pubmed: 34691040
Biochem Biophys Res Commun. 2017 Jun 03;487(3):709-715
pubmed: 28442344
Cell Death Dis. 2017 Mar 23;8(3):e2688
pubmed: 28333142
Oncoimmunology. 2020 Apr 7;9(1):1740477
pubmed: 33457088
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Liver Int. 2022 Aug;42(9):2042-2054
pubmed: 34894051
Curr Probl Cancer. 2019 Feb;43(1):18-26
pubmed: 29776595
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Methods Mol Biol. 2018;1655:335-350
pubmed: 28889395
Mutat Res Rev Mutat Res. 2022 Jan-Jun;789:108412
pubmed: 35690415

Auteurs

Ti Zhou (T)

Department of General Surgery, The First People's Hospital of Lin ping District, Hangzhou, Zhejiang, China.

Luqing Liu (L)

Department of General Surgery, The People's Hospital of Guannan County, Lianyungang, Jiangsu, China.

Haibin Lan (H)

Department of General Surgery, The First People's Hospital of Lin ping District, Hangzhou, Zhejiang, China.

Donglin Fang (D)

Department of General Surgery, The First People's Hospital of Lin ping District, Hangzhou, Zhejiang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH